Gilead Sciences reported additional data from the company’s Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19. 

A look at the U.S. Food and Drug Administration’s drug approval review calendar.

The U.S. Food and Drug Administration approved Evofem Biosciences Inc.’s Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Pregnant women are no more likely to become severely ill with COVID-19 than other women, according to a preliminary study in Britain, but most expectant mothers who do develop serious illness tend to be in the later stages of pregnancy.

Amphora has the opportunity to completely disrupt the birth control market with a new viscous and bioadhesive contraceptive.

The U.S. Food and Drug Administration approved South African drugmaker Aspen Pharmacare’s hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women.

China government officials told the Xinhua News Agency that the researcher who became world famous for using CRISPR on human embryos “will be transferred to public security authorities,” and the individuals involved in the research will be “severely dealt with according to the law.”

Evofem Biosciences shares rose 38 percent after the company’s birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.

The U.S. Food and Drug Administration approved the first test – a diagnostic from Meridian Bioscience Inc. – to help detect a type of herpes virus in newborns.